ReviewBioactive materials2022
Reactive oxygen species-based nanomaterials for the treatment of myocardial ischemia reperfusion injuries.
Review in Bioactive materials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed.
- Application of nanotherapy in cardiovascular diseases featuring novel pharmacological mechanisms and drug delivery strategies.Discover nano · 2026Review
- Peptide nanoarchitectonics of biomimetic nanozyme synergistically inhibits smooth muscle cell proliferation and promotes endothelial repair to reduce poststenting complications.Journal of nanobiotechnology · 2026Article
- Yam glycoprotein mediated the immunomodulation of macrophages by targeting TLR4.Molecular biology reports · 2026Article
- Quantitative design principles for biofunctional metal-organic frameworks: Stability thresholds, biointerface energetics, and therapeutic applications.Materials today. Bio · 2026Review
- A dual-pronged strategy: multi-bioactive nanoplatform synergizes ROS antidote and iron stabilization to protect against liver ischemia-reperfusion injury.Journal of nanobiotechnology · 2026Article
- A therapeutic relay strategy enabled by spatiotemporally programmable nanoplatforms for multilayered cardioprotection against MI/RI.Journal of nanobiotechnology · 2026Article
- Asymmetric nanozymes improve cardiac purine catabolism and alleviate oxidative stress of myocardium to treat ischemic heart disease.Journal of nanobiotechnology · 2026Article
- Modulation of Cell Signaling Pathways in Silica Nanoparticle-Saturated Macrophages.Pharmaceutics · 2026Article
- Integrative transcriptomic analysis identifies an oxidative stress-associated diagnostic signature for myocardial infarction.Journal of thrombosis and thrombolysis · 2026Article
- Platelet membrane biomimetic nanoparticle-based targeted delivery system of simvastatin for the treatment of ischemic stroke.PloS one · 2026Article
- Oxidoreductase-Like Nanozymes: From Biosensing to Molecular Mechanisms in Disease Therapy.International journal of nanomedicine · 2026Review
- Targeting a specific subset of neutrophils to mitigate cardiac reperfusion injury.Research square · 2025Article
- In vivo imaging of reactive oxygen species after myocardial ischemia-reperfusion injury: a large animal multimodal imaging and transcriptomic study.bioRxiv : the preprint server for biology · 2025Article
- Redox Signaling Disruption and Antioxidants in Toxicology: From Precision Therapy to Potential Hazards.Cell biochemistry and biophysics · 2025Review
- A Metalloporphyrin Nanosystem Enables Non-Invasive Visualization and Specific Treatment for Thrombosis and Ischemic Stroke.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Organ-protective effects of fullerenol and desflurane in a rat model of ischemia-reperfusion injury.Scientific reports · 2025Article
- Single-atom Pt-doped ceria nanozymes mitigate myocardial ischemia reperfusion injury via cardiomyocyte-targeted uptake and suppression of reactive oxygen species.Bioactive materials · 2025Article
- Polydopamine as a biocompatible and precise mitochondrial targeted therapeutic platform for reversing myocardial ischemia-reperfusion injury.Bioactive materials · 2025Article
- Advancements in nanomedicine for modulating ischemic cardiomyopathy therapy.Materials today. Bio · 2025Review
- Hybrid biomaterials-based radiosensitizers: Preparations and their applications in enhancing tumor radiotherapy.Materials today. Bio · 2025Article
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interventional coronary reperfusion strategies are widely adopted to treat acute myocardial infarction, but morbidity and mortality of acute myocardial infarction are still high. Reperfusion injuries are inevitable due to the generation of reactive oxygen species (ROS) and apoptosis of cardiac muscle cells. However, many antioxidant and anti-inflammatory drugs are largely limited by pharmacokinetics and route of administration, such as short half-life, low stability, low bioavailability, and side effects for treatment myocardial ischemia reperfusion injury. Therefore, it is necessary to develop effective drugs and technologies to address this issue. Fortunately, nanotherapies have demonstrated great opportunities for treating myocardial ischemia reperfusion injury. Compared with traditional drugs, nanodrugs can effectively increase the therapeutic effect and reduces side effects by improving pharmacokinetic and pharmacodynamic properties due to nanodrugs' size, shape, and material characteristics. In this review, the biology of ROS and molecular mechanisms of myocardial ischemia reperfusion injury are discussed. Furthermore, we summarized the applications of ROS-based nanoparticles, highlighting the latest achievements of nanotechnology researches for the treatment of myocardial ischemia reperfusion injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.